Skip to main content

Table 3 Therapeutic support at the entry date and associations with case status (death)

From: Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil

  All Death Survival Transplant HR (95% CI) p-values
Subjects (n) 39 20 (51.3) 3 (7.7) 16 (41.0)   
Dornase alfa (yes) 39 (100.0) 20 (100.0) 3 (100.0) 16 (100.0)
Colistin inhalation (yes) 38 (97.4) 20 (100.0) 2 (66.7) 16 (100.0) 0.05 (0.0–472.26) 0.511
Tobramycin inhalation (yes) 19 (48.7) 15 (75.0) 1 (33.3) 3 (18.8) 3.82 (1.38–10.60) 0.010
Azithromycin (yes) 33 (84.6) 16 (80.0) 3 (100.0) 14 (87.5) 1.32 (0.44–4.01) 0.622
Oxygen therapy (yes) 19 (48.7) 10 (50.0) 3 (100.0) 6 (37.5) 0.55 (0.22–1.36) 0.191
Pulmonary Exacerbations in the last year, median IR) 3 (1) 3 (1) 2(0) 3 (3) 0.86 (0.61–1.21 0.392
Hospital admission in the last year (n), median (IR) 2.1 (2.0) 2.0 (2.0) 0 (0.0) 2.0 (1.0) 1.21 (0.91–1.61) 0.198
NIMV in the last year (yes) 6 (15.4) 2 (10.0) 1 (33.3) 3 (18.8) 0.73 (0.17–3.23) 0.692
ICU admission in the last year (yes) 7 (17.9) 2 (10.0) 1 (33.3) 4 (25.0) 0.75 (0.17–3.43) 0.713
Mechanical ventilation (yes) 5 (12.8) 2 (10.0) 1 (33.3) 2 (12.5) 2.33 (0.51–10.8) 0.278
  1. Data are presented as n (%), median ± standard deviation or median (interquartile range). Hazard ratios (HRs) were derived from Cox regression models. CI confidence interval, NIMV non-invasive mechanical ventilation, ICU intensive care unit